Skip to main content
SpringerLink
Log in

Fenofibrate: a guide to its use in dyslipidaemia

  • Clinical Questions & Answers on Drugs
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Fenofibrate improves the lipid profile (particularly triglyceride and high-density lipoprotein-cholesterol levels) when administered alone or combined with a statin in patients with dyslipidaemia, and is generally well tolerated. Fenofibrate appears to decrease cardiovascular events in patients with type 2 diabetes mellitus and atherogenic dyslipidaemia, and may also reduce the risk of certain microvascular outcomes in patients with type 2 diabetes, although further investigation is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002 Dec 17; 106(25): 3143–421

    Google Scholar 

  2. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias Eur Heart J 2011; 32: 1769–818

    Article  Google Scholar 

  3. McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs 2011; 71(16): 1917–46

    Article  PubMed  CAS  Google Scholar 

  4. Abbott Healthcare Products Limited. Lipantil® Micro 200 mg capsules: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/684/SPC/Lipantil+Micro+200 [Accessed 2012 Jan 5]

  5. Abbott Healthcare Products Limited. Supralip® 160 mg film-coated tablet: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/3719/SPC/Supralip+160mg/ [Accessed 2012 Jan 5]

  6. Abbott Healthcare Products Limited. Lipantil Supra 145 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.medicines.ie/medicine/11695/SPC/Lipantil+Supra+145mg+film-coated+tablets/ [Accessed 2012 Jan 5]

  7. Abbott Healthcare Products Limited. Lipantil® Micro 67 mg capsules: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/683/SPC/Lipantil+Micro+67/ [Accessed 2012 Jan 5]

  8. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 Nov 26; 366(9500): 1849–61

    Article  PubMed  CAS  Google Scholar 

  9. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 2001 Mar 24; 357(9260): 905–10

    Article  Google Scholar 

  10. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 Apr 29; 362(17): 1563–74

    Article  Google Scholar 

  11. Genest Jr J, Nguyen N-H, Theroux P, et al. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J Cardiovasc Pharmacol 2000 Jan; 35(1): 164–72

    Article  PubMed  CAS  Google Scholar 

  12. Krempf M, Rohmer V, Farnier M, et al. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia. Diabetes Metab 2000 May; 26(3): 184–91

    PubMed  CAS  Google Scholar 

  13. Rosenson RS, Wolff DA, Huskin AL, et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007 Aug; 30(8): 1945–51

    Article  PubMed  CAS  Google Scholar 

  14. Duez H, Lefebvre B, Poulain P, et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor a modulation. Arterioscler Thromb Vasc Biol 2005 Mar; 25(3): 585–91

    Article  PubMed  CAS  Google Scholar 

  15. Insua A, Massari F, Rodriguez Moncalvo JJ, et al. Fenofibrate or gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract 2002 Mar; 8(2): 96–101

    PubMed  Google Scholar 

  16. Ansquer J-C, Corda C, Le MK, et al. Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: a 12-week, multicenter, randomized, open-label, parallel-group study. Curr Ther Res Clin Exp 2009; 70(2): 71–93

    Article  CAS  Google Scholar 

  17. Després JP, Lemieux I, Salomon H, et al. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. J Intern Med 2002 Jun; 251(6): 490–9

    Article  PubMed  Google Scholar 

  18. Malik J, Melenovsky V, Wichterle D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (Fenofibrate versus Atorvastatin Trial: FAT). Cardiovasc Res 2001 Nov; 52(2): 290–8

    Article  PubMed  CAS  Google Scholar 

  19. Ducobu J, VanHaelst L, Salomon H. Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia. J Cardiovasc Pharmacol 2003; 41(1): 60–7

    Article  PubMed  CAS  Google Scholar 

  20. Farnier M, Bonnefous F, Debbas N, et al. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994 Feb 28; 154: 441–9

    Article  PubMed  CAS  Google Scholar 

  21. Steinmetz A, Schwartz T, Hehnke U, et al. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol 1996 Apr; 27(4): 563–70

    Article  PubMed  CAS  Google Scholar 

  22. Wi J, Kim J-Y, Park S, et al. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160mg and niacin 1500mg. Atherosclerosis 2010; 213(1): 235–40

    Article  PubMed  CAS  Google Scholar 

  23. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002 Jul; 25(7): 1198–202

    Article  PubMed  CAS  Google Scholar 

  24. Derosa G, Cicero AE, Bertone G, et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 2004 Oct; 26(10): 1599–607

    Article  PubMed  CAS  Google Scholar 

  25. Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004 May; 64(2): 137–51

    Article  PubMed  CAS  Google Scholar 

  26. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006 Jul 18; 48(2): 396–401

    Article  PubMed  CAS  Google Scholar 

  27. Davidson MH, Rooney MW, Drucker J, et al. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther 2009 Dec; 31(12): 2824–38

    Article  PubMed  CAS  Google Scholar 

  28. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005 May 17; 45(10): 1649–53

    Article  PubMed  CAS  Google Scholar 

  29. Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Am J Cardiol 2010 Sep 15; 106(6): 787–92

    Article  PubMed  CAS  Google Scholar 

  30. Farnier M, Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol 2000 Jan 1; 85(1): 53–7

    Article  PubMed  CAS  Google Scholar 

  31. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005 Feb 15; 95(4): 462–8

    Article  PubMed  CAS  Google Scholar 

  32. Farnier M, Steinmetz A, Retterstol K, et al. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clin Ther 2011 Jan; 33(1): 1–12

    Article  PubMed  CAS  Google Scholar 

  33. Hiukka A, Leinonen E, Jauhiainen M, et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007 Oct; 50(10): 2067–75

    Article  PubMed  CAS  Google Scholar 

  34. Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009 Mar; 32(3): 493–8

    Article  PubMed  CAS  Google Scholar 

  35. Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009 May 23; 373(9677): 1780–8

    Article  PubMed  CAS  Google Scholar 

  36. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007 Nov 17; 370(9600): 1687–97

    Article  PubMed  CAS  Google Scholar 

  37. Davis TME, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011; 54(2): 280–90

    Article  PubMed  CAS  Google Scholar 

  38. Ting R-D, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study. Diabetes Care 2012 Feb; 35(2): 218–25

    Article  PubMed  CAS  Google Scholar 

  39. Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Curr Opin Lipidology 2011; 22(1): 55–61

    Article  CAS  Google Scholar 

  40. Fruchart JC, Sacks FM, Hermans MP. Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i). Curr Med Res Opin 2010 Aug; 26(8): 1793–7

    Article  PubMed  CAS  Google Scholar 

  41. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 Jul 15; 363(3): 233–44

    Article  PubMed  Google Scholar 

Download references

Acknowledgements and Disclosures

This article was adapted from Drugs 2011; 71 (16): 1917–46,[3] and reviewed by D. Bhatnagar, Diabetes Centre, The Royal Oldham Hospital, Oldham, UK; M. Farnier, Point Médical, Rond Point de la Nation, Dijon, France.

The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Gillian M. Keating & Kate McKeage

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G.M., McKeage, K. Fenofibrate: a guide to its use in dyslipidaemia. Drugs Ther Perspect 28, 5–10 (2012). https://doi.org/10.2165/11608570-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11608570-000000000-00000

Keywords

Search

Navigation